|
gptkbp:instanceOf
|
antiviral drug
prodrug
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AB11
|
|
gptkbp:bioavailability
|
54%
|
|
gptkbp:brand
|
gptkb:Valtrex
|
|
gptkbp:CASNumber
|
124832-27-5
|
|
gptkbp:chemicalFormula
|
C13H20N6O4
|
|
gptkbp:contraindication
|
hypersensitivity to acyclovir
hypersensitivity to valacyclovir
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
2.5-3.3 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1990s
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valacyclovir
|
|
gptkbp:KEGGID
|
D02366
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA polymerase
|
|
gptkbp:metabolism
|
gptkb:acyclovir
|
|
gptkbp:molecularWeight
|
324.33 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:prescribes
|
immunocompromised patients
HIV patients (for herpes suppression)
prevention of cytomegalovirus infection in transplant patients
|
|
gptkbp:prodrugOf
|
gptkb:acyclovir
|
|
gptkbp:proteinBinding
|
13-18%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1435
135398744
DB00577
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
abdominal pain
dizziness
headache
rash
|
|
gptkbp:UNII
|
61OQ44D3UN
|
|
gptkbp:usedFor
|
gptkb:chickenpox
shingles
genital herpes
herpes simplex virus infection
herpes zoster
varicella zoster virus infection
cold sores
|
|
gptkbp:bfsParent
|
gptkb:Antiviral
|
|
gptkbp:bfsLayer
|
6
|